Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

13.01.20	Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. (GlobeNewswire)
13.12.19	Biogen Stops Development Of Gosuranemab For Progressive Supranuclear Palsy (RTTNews)
13.12.19	Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy (GlobeNewswire)
03.12.19	Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
22.11.19	Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity (RTTNews)
22.11.19	Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) (GlobeNewswire)
21.11.19	Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder (GlobeNewswire)
06.11.19	Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis (GlobeNewswire)
04.11.19	Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 (GlobeNewswire)
30.10.19	Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis (GlobeNewswire)
23.10.19	Biogen CEO Confident Its Alzheimer's Drug Will Get FDA Approval (RTTNews)
22.10.19	Biogen Q3 Profit Tops Estimates; Revenue Up 5% - Quick Facts (RTTNews)
22.10.19	Biogen Plans To Submit BLA For Aducanumab In Alzheimer's Disease; Shares Jump (RTTNews)
22.10.19	Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies (GlobeNewswire)
21.10.19	Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week (GlobeNewswire)
03.10.19	Biogen Canada Reports Positive Results On Spinal Muscular Atrophy Study (RTTNews)
02.10.19	Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders (GlobeNewswire)
01.10.19	Biogen Appoints Alfred Sandrock As EVP, Research And Development (RTTNews)
01.10.19	Biogen Announces Leadership Update (GlobeNewswire)
23.09.19	Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding (GlobeNewswire)
18.09.19	Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients (GlobeNewswire)
17.09.19	Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index (GlobeNewswire)
13.09.19	Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts (RTTNews)
12.09.19	New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum (GlobeNewswire)
11.09.19	New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years (GlobeNewswire)
30.07.19	ALKS : Diroximel Fumarate Shows Superior GI Tolerability On EVOLVE-MS-2 Endpoint (RTTNews)
30.07.19	Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis (GlobeNewswire)
23.07.19	Biogen Q2 Profit Rises; Lifts 2019 Outlook (RTTNews)
22.07.19	Notable Earnings To Watch On July 23 - AN, JBLU, BIIB, CMG, KO, HOG, HAS, TXN (RTTNews)
01.07.19	Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients (GlobeNewswire)
29.06.19	Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy (GlobeNewswire)
12.06.19	Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 (GlobeNewswire)
11.06.19	Genentech: Gazyva Meets Endpoints In Phase II Lupus Nephritis Trial (RTTNews)
07.06.19	Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million (GlobeNewswire)
07.06.19	Pain, Pain Go Away - The Suicide Disease Drug Pipeline (RTTNews)
30.05.19	New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis (GlobeNewswire)
20.05.19	Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation (GlobeNewswire)
07.05.19	Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS (GlobeNewswire)
06.05.19	Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen) (GlobeNewswire)
01.05.19	Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
01.05.19	Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases (GlobeNewswire)
30.04.19	Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy (GlobeNewswire)
29.04.19	Biogen Announces Three New Nominees for Election to Board of Directors (GlobeNewswire)
24.04.19	Biogen Inc. Q1 adjusted earnings Beat Estimates (RTTNews)
12.04.19	Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference (GlobeNewswire)
25.03.19	Biogen Announces $5 Bln Stock Buyback (RTTNews)
21.03.19	Biogen Shares Fall As Late-stage Trials Of Alzheimer's Drug Discontinued (RTTNews)
21.03.19	Biogen, Eisai To Discontinue Phase 3 ENGAGE, EMERGE Trials Of Aducanumab (RTTNews)
21.03.19	Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease (GlobeNewswire)
12.03.19	Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		Gewinne in Frankfurt: LUS-DAX steigt schlussendlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Starker Wochentag in Frankfurt: DAX bewegt sich zum Ende des Freitagshandels im Plus

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

Gewinne in Frankfurt: LUS-DAX steigt schlussendlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

DAX-Handel aktuell: DAX nachmittags mit positivem Vorzeichen